

PATENT

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application
Commissioner of Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing is the patent application
under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: **USAV2002/0098USNP**

INVENTORS: **Li et al.**

TITLE: **METHOD FOR ASSAYING COMPOUNDS OR AGENTS
FOR ABILITY TO DECREASE THE ACTIVITY OF MICROSOMAL
PROSTAGLANDIN E SYNTHASE OR HEMATOPOIETIC
PROSTAGLANDIN D SYNTHASE**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to Mail Stop
Patent Application, Commissioner of Patents, P.O.
Box 1450, Alexandria, VA 22313-1450, on

Date of Deposit 8/15/03

Signature [Signature]

Express Mail No. **EV330283003US**

19972 U.S. PTO
10/642468



APPLICATION ELEMENTS

1. ☒ *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Specification Total Pages
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) Total Sheets
4. Oath or Declaration Total Pages
 - a. ☒ Unexecuted (original or copy)
 - b. ☐ Copy from a prior application (37 CFR § 1.63(d))
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior
application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).
5. Power of Attorney Total Pages
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 CFR § 1.63(d))
6. ☐ Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission

(if applicable, all necessary)

- a. ☒ Computer Readable Copy
 b. ☒ Paper Copy (identical to computer copy)
 c. ☒ Statement verifying identity of above copies

☐ If a **CONTINUING** Application, check appropriate box, and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part

of prior application no: _____, filed _____,

Examiner _____, Group/Art Unit _____.

(The cross reference has been/will be inserted on page one of the specification).

- ☒ This application claims the benefit of U.S. Provisional Application No. **60/404,008**,
 filed **August 16, 2002** and Great Britain Application No. **0229244.9** filed **December 16, 2002**
 (The cross reference has been/will be inserted on page one of the specification).

☐ **Incorporation By Reference** (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS


7. ☐ Assignment Papers (cover sheet & document(s))
 8. ☐ 37 CFR §3.73(b) Statement
 (when there is an assignee)
 9. ☐ Verified English Translation Document (if applicable)
 10. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
 11. ☐ Preliminary Amendment
 12. ☒ Return Receipt Postcard (MPEP 503)
 (Should be specifically itemized)
 13. ☐ *Small Entity Statement(s) ☐ Statement filed in prior application,
 (PTO/SB/09-12) Status still proper and desired
 14. ☐ Certified Copy of Priority Document(s)
 (if foreign priority is claimed)
 15. ☒ Other: Application Data Sheet

CORRESPONDENCE ADDRESS

- ☒ Customer Number or Bar Code Label

005487

(Insert Customer No. or Attach bar code label here)


 William C. Coppola, Reg. No. 41,686

Aventis Pharmaceuticals Inc.
 Patent Department
 Route #202-206 / P.O. Box 6800
 Bridgewater, New Jersey 08807-0800
 Telephone (908) 231-4854
 Telefax (908) 231-2626
 Aventis Docket No. **USAV2002/0098USNP**

08/15/03

17707 U.S. PTO

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL
for FY 2003**

Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT** (\$ 978.00)

PTO/SB/17 (01-03)

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Application Number	To Be Assigned
Filing Date	Herewith
First Named Inventor	Li et al.
Examiner Name	To Be Assigned
Group / Art Unit	To Be Assigned
Attorney Docket No.	USAV2002/0098USNP

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None☒ Deposit AccountDeposit
Account
Number
Deposit
Account
Name

18-1982

Aventis Pharmaceuticals Inc.

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments
☒ Charge any additional fee(s) during the pendency of this application
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity	Fee Code	Fee (\$)	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
	1001	750		2001	375	Utility filing fee	750
	1002	330		2002	165	Design filing Fee	
	1003	520		2003	260	Plant filing fee	
	1004	750		2004	375	Reissue filing fee	
	1005	160		2005	80	Provisional filing fee	

SUBTOTAL (1) (\$ 750.00)**2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE**

Total Claims	Extra Claims	Fee from below	Fee Paid
28	-20**= 8	18	144
Independent 4	- 3**= 1	84	84
Claims			
Multiple Dependent			

Large Entity	Fee Code	Fee (\$)	Small Entity	Fee Code	Fee (\$)	Fee Description
	1202	18		2202	9	Claims in excess of 20
	1201	84		2201	42	Independent claims in excess of 3
	1203	280		2203	140	Multiple dependent claim, if not paid
	1204	84		2204	42	**Reissue independent claims over original patent
	1205	18		2205	9	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 228.00)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity	Fee Code	Fee (\$)	Small Entity	Fee Code	Fee (\$)	Fee Description
	1051	130		2051	65	Surcharge - late filing fee or oath
	1052	50		2052	25	Surcharge - late provisional filing fee or cover sheet
	1053	130		1053	130	Non-English Specification
	1812	2,520		1812	2,520	For filing a request for reexamination
	1804	920*		1804	920*	Requesting publication of SIR prior to Examiner action
	1805	1,840*		1805	1,840*	Requesting publication of SIR after Examiner action
	1251	110		2251	55	Extension for reply within first month
	1252	410		2252	205	Extension for reply within second month
	1253	930		2253	465	Extension for reply within third month
	1254	1,450		2254	725	Extension for reply within fourth month
	1255	1970		2255	985	Extension for reply within fifth month
	1401	320		2401	160	Notice of Appeal
	1402	320		2402	160	Filing a brief in support of an appeal
	1403	280		2403	140	Request for oral hearing
	1451	1,510		1451	1,510	Petition to institute a public use proceeding
	1452	110		2452	55	Petition to revive - unavoidable
	1453	1,300		2453	650	Petition to revive - unintentional
	1501	1,300		2501	650	Utility issue fee (or reissue)
	1502	470		2502	235	Design issue fee
	1503	630		2503	315	Plant issue fee
	1460	130		1460	130	Petitions to the Commissioner
	1807	50		1807	50	Petitions related to provisional applications
	1806	180		1806	180	Submission of Information Disclosure Stmt
	8021	40		8021	40	Recording each patent assignment per property (times number of properties)
	1809	750		2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))
	1810	750		2810	375	For each additional invention to be examined (37 CFR § 1.129(b))
	1801	750		2801	375	Request for Continued Examination (RCE)
	1802	900		1802	900	Request for expedited examination of a design application

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)**SUBMITTED BY**

Name (Print/Type)	William C. Goppola	Registration No. (Attorney/Agent)	41,686	Telephone	(908) 231-4854
Signature				Date	August 15, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template

19970 U.S. PTO

10/642468

08/15/03